Tony Adamis

About Tony Adamis

Tony Adamis

Vice President and Global Head of Ophthalmology, Genentech.

Anthony Adamis has had two careers in ophthalmology: one as a clinician and a second as an industry executive. One of the team who discovered the role that VEGF plays in retinal neovascularization, Adamis also participated in the development and launch of pegaptanib, the first anti-VEGF agent approved for use in ophthalmology. He was also part of the team who discovered that, in ocular models of neovascular growth, the addition of an anti-PDGF agent to anti-VEGF therapy is more effective than an anti-VEGF agent alone in enhancing vessel regression.